Abstract
Tuberculosis (TB), an ongoing public health threat, is worsened by the emergence of drug resistance. With an estimated 630000 cases per year of multidrug resistant (MDR)-TB, and 9% of those being extensively drug resistant (XDR)-TB, there is an urgent need for new and more effective anti-TB drugs. New TB treatment regimens should be able to shorten the duration of therapy that currently takes at least six months. The non-compliance with this long treatment duration is one of the reasons for the development of drug resistance. In spite of the difficulties and alleged lack of interest from the pharmaceutical industry for the discovery and development of new antibiotics, several new or repurposed drugs are being evaluated in clinical trials. This review article summarizes the information available and presents an update on the drugs currently in clinical trials for TB and briefly introduces some new compounds in pre-clinical development.
Keywords: Antibiotics, clinical trials, drug development, drug resistance, tuberculosis.
Current Medicinal Chemistry
Title:Tuberculosis Clinical Trial Update and the Current Anti-Tuberculosis Drug Portfolio
Volume: 20 Issue: 30
Author(s): Juan Carlos Palomino and Anandi Martin
Affiliation:
Keywords: Antibiotics, clinical trials, drug development, drug resistance, tuberculosis.
Abstract: Tuberculosis (TB), an ongoing public health threat, is worsened by the emergence of drug resistance. With an estimated 630000 cases per year of multidrug resistant (MDR)-TB, and 9% of those being extensively drug resistant (XDR)-TB, there is an urgent need for new and more effective anti-TB drugs. New TB treatment regimens should be able to shorten the duration of therapy that currently takes at least six months. The non-compliance with this long treatment duration is one of the reasons for the development of drug resistance. In spite of the difficulties and alleged lack of interest from the pharmaceutical industry for the discovery and development of new antibiotics, several new or repurposed drugs are being evaluated in clinical trials. This review article summarizes the information available and presents an update on the drugs currently in clinical trials for TB and briefly introduces some new compounds in pre-clinical development.
Export Options
About this article
Cite this article as:
Palomino Carlos Juan and Martin Anandi, Tuberculosis Clinical Trial Update and the Current Anti-Tuberculosis Drug Portfolio, Current Medicinal Chemistry 2013; 20 (30) . https://dx.doi.org/10.2174/09298673113209990166
DOI https://dx.doi.org/10.2174/09298673113209990166 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Open Source Software and Web Services for Designing Therapeutic Molecules
Current Topics in Medicinal Chemistry An Evolving Role of Piperazine Moieties in Drug Design and Discovery
Mini-Reviews in Medicinal Chemistry Adverse Drug Reactions in a Pulmonary Teaching Hospital: Incidence, Pattern, Seriousness, and Preventability
Current Drug Safety New Patentable Use of an Old Neuroleptic Compound Thioridazine to Combat Tuberculosis: A Gene Regulation Perspective
Recent Patents on Anti-Infective Drug Discovery Evaluation of the Combined Therapy of DA-7218, a New Oxazolidinone, and Trimethoprim/ Sulfamethoxazole in the Treatment of Experimental Actinomycetoma by Nocardia brasiliensis
Current Drug Delivery Radiolabelled Peptides: Eon in Radiopharmaceutical
Current Radiopharmaceuticals MolDock Applied to Structure-Based Virtual Screening
Current Drug Targets Dendritic Cells and Macrophages: Same Receptors but Different Functions
Current Immunology Reviews (Discontinued) Mobile Phone Based Biomedical Imaging Technology: A Newly Emerging Area
Recent Patents on Biomedical Engineering (Discontinued) Secondary Metabolites Derived from Actinomycetes: Iron Modulation and Their Therapeutic Potential
The Natural Products Journal Editorial: [A Threat to One is a Threat to All – Biosecurity for the Western World Starts in Developing Countries: Do We Speak the Same Language of Hygiene?]
Inflammation & Allergy - Drug Targets (Discontinued) Cannabinoids and Schizophrenia: Therapeutic Prospects
Current Pharmaceutical Design A New Catalytic Method for Eco-Friendly Synthesis of Quinoxalines by Zirconium (IV) Oxide Chloride Octahydrate Under Mild Conditions
Letters in Organic Chemistry Synthesis and Characterization of 1-carboxyphenothiazine Derivatives Bearing Nitrogen Mustard as Promising Class of Antitubercular Agents
Letters in Drug Design & Discovery Multiple-Dose Pharmacokinetics of Efavirenz with and without the Use of Rifampicin in HIV-Positive Patients
Current HIV Research Positron Emission Tomography in the Diagnosis and Treatment Management of Tuberculosis
Current Pharmaceutical Design AMPA Receptor Potentiators as Novel Antidepressants
Current Pharmaceutical Design A Dilemma of Functional Genomics: Count the Chickens or Study their Eggs ?
Current Genomics From the Old Immunitas to the Modern Immunity: Do We Need a New Name for the Immune System?
Current Immunology Reviews (Discontinued) Chemical Constituents and Biological Activities of Simira Genus: A Contribution to the Chemotaxonomic of Rubiaceae Family
The Natural Products Journal